Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Joshua Friedman(Icahn School of Medicine at Mount Sinai), Adı́lia Hormigo(Icahn School of Medicine at Mount Sinai), Kambiz Nael(University of California, San Francisco), Priyanka Kadaba(Icahn School of Medicine at Mount Sinai), Nadejda M. Tsankova(Allen Institute for Brain Science), Puneet Belani(Icahn School of Medicine at Mount Sinai), Ethan Ellis(Icahn School of Medicine at Mount Sinai), Tomi Jun(Sema4 (United States)), Omid Rashidipour(Icahn School of Medicine at Mount Sinai), Robert Sebra(Sema4 (United States)), Kuan‐lin Huang(Icahn School of Medicine at Mount Sinai)
Cited by 9
Related Papers
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
|Nature Communications|2017|153
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
|Cancer Cell|2022|127
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
|Nature Communications|2018|98
Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
|Nature Communications|2023|98
A clinical benchmark of public self-supervised pathology foundation models
|Nature Communications|2025|78